Research across Cancer
Related studies from across the Cancer family.
42 trials tracked for Prostate adenocarcinoma: 8 in phase 3 or 4 and 5 with published results. The most-cited published study has 301 citations.
Showing the 42 most-cited and recently-updated of 42 trials. Browse the full registry →
Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.
Short-term androgen deprivation has been shown to significantly improve clinical outcomes in prostate adenocarcinoma, with a 90% vs 81% rate of biochemical disease-free survival at 5 years (p=0.01), an 83% vs 94% metastasis-free survival rate (p=0.01), and an 86% vs 95% overall survival rate at 5 years (p=0.009) 5.
Imaging modalities including 68Ga-RM2 6, 68Ga-PSMA-11 7, Ga-PSMA-11 9, C-11 choline PET tracer 11, and 18F-DCFPyL have been evaluated in clinical trials. Notably, 131 participants had their intended treatment plans changed based on 18F-DCFPyL PET/CT imaging results 10.
Self-administered nitrous oxide was evaluated in a Phase 4 trial 4. Additionally, hypofractionated radiation therapy did not show statistically significant differences in the urinary or bowel domains of the Expanded Prostate Cancer Index (EPIC) at two years 8.
AI synthesis of 11 cited trials, updated Jun 25, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.
Related studies from across the Cancer family.